Search the Newsreel

Olema Pharmaceuticals falls 6% on second quarter EPS miss

Olema Pharmaceuticals (NASDAQ:OLMA) reported a second-quarter loss of $0.61 per share, missing analyst estimates by $0.06, leading to a 5.8% stock decline. The company's net loss increased to $63.2 million due to higher spending on clinical development for breast cancer therapies palazestrant and OP-3136. …

Olema Pharmaceuticals Q2 Loss Widens

NULL

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Olema Oncology announced its financial and operating results for the second quarter of 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also reported initial Phase 1 clinical data for OP-3136, …

Emera (TSX:EMA), Why Is It Back In Focus?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. What Emera's latest earnings mean for investors Emera (TSX:EMA) has just released its second quarter 2026 results, giving investors fresh detail on revenue, profit and earnings per …

ALBEMARLE AKTIE: AI-Analysen, Prognose & Kursziel

AlTi Global (NASDAQ:ALTI) Issues Quarterly Earnings Results

Olema Pharmaceuticals Q2 Results: EPS misses estimates, losses widen

Olema Pharmaceuticals reported a Q2 EPS of $(0.61), missing the analyst consensus of $(0.55) by 10.91%. This represents a 19.61% increase in losses year-over-year from $(0.51), indicating persistent profitability challenges. The company's financial trajectory suggests a disconnect between market expectations and its current performance, …

Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss

Olema Pharmaceuticals (OLMA) reported a Q2 loss per share of $0.61, which is wider than the FactSet estimated loss of $0.55 per share. The company is a clinical-stage biopharmaceutical company focused on breast cancer treatments. The article also mentions recent news regarding their clinical …

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS

Olema Pharmaceuticals (NASDAQ:OLMA) reported a quarterly loss of $0.61 per share, missing analysts' consensus estimate by $0.08. The company's stock traded down to $11.94, with a market capitalization of $1.04 billion. Despite missing estimates, Wall Street analysts maintain a "Moderate Buy" consensus rating with …

$OLMA ($OLMA) Releases Q2 2026 Earnings

MarineMax Inc. (FL) (HZO) Stock Price | Live Quotes & Charts | NYSE

Emera Inc. Revenue Breakdown – OTC:ERRAF

Emera Inc. (OTC:ERRAF) reported a total revenue of $6.39 billion USD last year. The Florida Electric Utility segment was the top-performing division, contributing $3.16 billion USD, an increase from $2.40 billion USD in the previous year. The United States was the primary revenue source, …

MarineMax agrees to $1.5B all-cash sale

MarineMax, Inc. has agreed to an all-cash sale to Blackstone’s Safe Harbor Marinas for approximately $1.5 billion, or $53.00 per share. This transaction represents a significant premium to MarineMax's recent share prices and is the result of a strategic review process aimed at maximizing …

Shareholder Alert: Ademi LLP investigates whether MarineMax, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating MarineMax (NYSE: HZO) regarding potential breaches of fiduciary duty related to its recently announced $1.5 billion all-cash transaction with Safe Harbor Marinas. The firm is examining whether the $53.00 per share offer represents a fair price for public shareholders, especially …

HZO Stock Alert: Halper Sadeh LLC is Investigating Whether MarineMax, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of MarineMax, Inc. (NYSE: HZO) to Safe Harbor Marinas for $53.00 per share in cash. The firm is examining whether MarineMax and its board failed to secure the best possible price for …

Olema Pharmaceuticals earnings up next ahead of key trial data

Olema Pharmaceuticals is set to report its second-quarter results, with analysts expecting wider losses as the clinical-stage biotech continues to advance its breast cancer pipeline. Investors are keenly awaiting top-line data from its Phase 3 OPERA-01 trial, expected this fall, which will be crucial …

Alqemam for Computer Systems Inks Software Services Deal with Saudi Agency

Cinemark Holdings Inc Cinemark (CNK) Stock Forecasts

Argus has raised its target price for Cinemark Holdings Inc (CNK) to $40.00, with the company currently trading at $37.73. Cinemark is described as a geographically diverse operator in the motion picture exhibition industry in the United States. The report suggests accessing premium research …

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fresh clues on the …

OneMain Holdings, Inc. (NYSE:OMF) Is Largely Controlled by Institutional Shareholders Who Own 81% of the Company

OneMain Holdings, Inc. (NYSE:OMF) is primarily controlled by institutional shareholders, who own 81% of the company, indicating their trading actions significantly influence the stock price. The top 12 shareholders collectively own 50% of the company, with The Vanguard Group, Inc. being the largest at …

Gladstone Land to discuss farms and leases in Aug. 12 webcast

Gladstone Land Corporation (NASDAQ:LAND) will host its Q2 2026 earnings call and webcast on August 12, 2026, at 8:30 a.m. ET. The company, a real estate investment trust specializing in farm properties, will discuss its financial results for the quarter ended June 30, 2026. …

Gladstone Land Corporation Earnings Call and Webcast Information

Gladstone Land Corporation (Nasdaq:LAND) has announced the details for its Second Quarter Ended June 30, 2026, earnings call and webcast. The event is scheduled for Wednesday, August 12, 2026, at 8:30 a.m. ET, and will be accessible via webcast and phone. A replay of …

ALBEMARLE CORPORATION : MORGAN STANLEY CUTS TARGET PRICE TO $161.00 FROM $189.00

Morgan Stanley has adjusted its target price for Albemarle Corporation (ALB), reducing it to $161.00 from the previous $189.00. This update indicates a revised outlook from the investment bank regarding the company's valuation. The report was issued by Reuters.

Weekly Recap: Cinemark (CNK) cup-base breakout and record domestic box‑office weekend

Cinemark (CNK) is positioned near a 36.38 cup-base buy point, indicating a potential 34% upside to around $51 by early 2027. This projection is supported by the company's recent record-breaking domestic box office weekend, driven by strong sales from "Spider-Man: Brand New Day" and …

MarineMax soars after agreeing to a go-private deal

[3D Growth Graph on Blueprint with Measurement Tools Illustrating Planning and Progress] J Studios MarineMax (HZO [https://seekingalpha.com/symbol/HZO]) announced on Monday that it accepted a buyout offer from Safe Harbor at $53.00 per share. The all-cash transaction represents an enterprise value of approximately $1.5B. The …

LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?

LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% …

OneMain Holdings Inc's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Upcoming Payout and Long-Term Sustainability of OMF's Dividend OneMain Holdings Inc (NYSE:OMF) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-08-10. This upcoming payment includes a $1.05 per share …

Emami Paper Mills: ਸ਼ੇਅਰ ਹੋਇਆ ਬੁਲੰਦ! ਸਾਲਾਨਾ ਪ੍ਰੋਫਿਟ (PAT) ਵਿੱਚ **136%** ਦਾ ਜ਼ਬਰਦਸਤ ਵਾਧਾ

The Manufacturers Life Insurance Company Purchases 16,117 Shares of OneMain Holdings, Inc. $OMF

The Manufacturers Life Insurance Company increased its stake in OneMain Holdings, Inc. (NYSE:OMF) by 73.8% in the first quarter, purchasing an additional 16,117 shares. OneMain Holdings reported strong Q1 earnings, beating analyst estimates with an EPS of $1.31 and revenue of $1.62 billion, and …

MarineMax, Inc. (NYSE:HZO) Given Average Rating of "Moderate Buy" by Brokerages

Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT

Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing …

Assenagon Asset Management S.A. Raises Position in Albemarle Corporation $ALB

Assenagon Asset Management S.A. significantly increased its stake in Albemarle Corporation (NYSE:ALB) by 331.0% in the second quarter, now owning 203,996 shares worth $27.5 million. Other institutional investors like Earnest Partners LLC, Northern Trust Corp, Goldman Sachs Group Inc., Norges Bank, and Phoenix Financial …

Emami Paper Mills seeks approval for ₹3.20 dividend at 44th AGM

Femasys Enters $30 Mln Private Placement; Up To $90 Mln Potential Proceeds; Stock Down

(RTTNews) - Femasys Inc. (FEMY) announced that it has entered into a securities purchase agreement for a $30 million private placement of shares and warrants led by Nantahala Capital. Under the terms of the agreement, Femasys is selling to the investors an aggregate of …

Hemab Therapeutics Holdings (Nasdaq:COAG) - analisi del titolo

Hemab Therapeutics Holdings, Inc. (Nasdaq:COAG) is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders in the US and Denmark. The company's pipeline includes sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, HMB-002 for Von Willebrand Disease, and the newly …

Emera Q2 Earnings Call Highlights

Emera (TSE:EMA) reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as the utility advanced asset sales designed to strengthen its balance sheet and concentrate investment on its regulated businesses. Year-to-date adjusted earnings totaled C$627 million, up C$12 million from the prior-year …